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Editorial
According to the Institute of Medicine report medications are the
most common medical intervention. However, drug-related morbidity
and mortality now represents a major public health challenge due to
the ineffective and unsafe consequences of medication use. Morbidity
in this case relates to disease and illness associated with drug therapy
whereas mortality relates to death associated with drug therapy. It is
also estimated in the US that drug-related morbidity and mortality cost
about $200 billion annually in health care expenditure.
This is clearly a failure in our healthcare systems. In order to reduce
this drug-related morbidity and mortality we have to deal it with at the
clinical level, one patient at a time. The profession of Pharmacy
responded to this problem with the introduction of clinical pharmacy
in the mid-1960’s and included a number of services which were more
patient-focused and less product-focused. In this model, however, the
pharmacist was seen as a drug information provider and was less held
accountable for the drug therapy outcomes. In the 1990’s a major
paradigm shift in terms of philosophy of practice that included the care
concept and taking responsibility for drug therapy outcomes was
witnessed. Pharmaceutical care was born. It is defined by Linda Strand
and Hepler as a patient-centered practice in which the practitioner
assumes responsibility for a patient’s drug-related needs and is held
accountable for this commitment. The aim of this philosophy of
practice was the provision of responsible drug therapy for the purpose
of achieving positive patient outcomes.
In 2006 the Federal Government also responded to these drugrelated problems by implementing a new drug benefit (Part D) within
the federal insurance program of medicare, which includes a new
service to the elderly population. This new service was called
Medication Therapy Management (MTM). The purpose of the service
was primarily intended to reduce drug adverse events and reduce
drug-related cost among the elderly. There was, however, neither a
clear definition of MTM nor standards of care for providing the
services. Various definitions of MTM have been adopted by a number
of organizations including the American Pharmacists Association. In
sum, the emphasis in all these definitions is the face-to-face patient
assessment and appropriate interventions for the purpose of
optimizing response to drug therapy or to manage treatment-related
interactions or complications.
In terms of benefits of MTM, a number of studies have been carried
out including the Ashville project that demonstrated positive clinical
and economic impact. Specifically, the Minnesota Pharmaceutical Care
project demonstrated the use of a patient-centered model that
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addressed all the drug-related needs including appropriate indication
for the drug therapy, effectiveness of the drug regimen, the safety of the
drug regimen and patient’s adherence to prescription instructions.
Inasmuch there has been a significant growth of MTM services
there are still no clearly defined standards of care. The profession need
to adopt a patient care process that will enable Pharmacist Clinicians
identify, resolve and prevent drug therapy problems. This process is
well articulated in Pharmaceutical Care Practice textbook by Linda
Strand, Robert Cipolle and Morley. The process described is patientcentered and systematic. It is involves step-by-step set of activities
including assessment, care plan and follow up evaluation of drug
therapy outcomes.
Additionally, this patient care process articulates diagnosis of welldefined drug therapy problems with specific causes that can be
addressed and appropriately resolved using evidence-based practice
guidelines. If this approach were to be adopted clinicians globally will
be able to compare the outcomes of MTM services they provide.
Finally, it is quite evident that drug product provision, which
occupies the majority of the Pharmacists’ time, only addresses
compliance, leaving out the other three drug-related needs that must
be addressed. The Pharmacy profession must step up and address all
the four drug-related needs. Needless to say, more than 70% of
physician visits by patients have been reported to be due to
unsatisfactory drug therapy outcomes and less on new diagnoses.
Additionally, it has been reported that 1.5 million drug errors that
occur annually are preventable and that Pharmaceutical Care
Practitioners can resolve about 80% of drug therapy problems directly
with the patient. This goes to show the untapped potential role the
Pharmacist has in improving drug therapy outcomes.
We know that drugs do not work on their own. They need to be
managed in order to produce the desired outcomes. Medication
Therapy Management, therefore, becomes an important strategy for
delivering Pharmaceutical care. However, better models for providing
efficient and efficacious MTM service need to be developed along with
appropriate legislations that empower the Pharmacist clinicians make
the necessary interventions and bill for such services. To this end the
current push for provider status will go a long way to enhance
Pharmaceutical Care Practice.
We believe in not long future the Pharmacists will be running MTM
clinics, able to bill independently as health care providers and be held
accountable for drug therapy outcomes.
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